Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative drugs operate by mimicking the natural actions of GLP-1, a hormone secreted by the gut in response to consumption. By stimulating GLP-1 receptors in the pancreas, these compounds enhance insulin release and inhibit glu

The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight decrease – they exhibit intriguing difference